Home > Dermatology > PFGC 2021 > Best of the Posters > Secukinumab also tolerable in paediatric psoriasis patients

Secukinumab also tolerable in paediatric psoriasis patients

Presented By
Prof. Michael Sticherling, University Erlangen–Nürnberg, Germany
PFGC 2021
The safety of a biologic is a key concern in children with psoriasis. A pooled safety analysis of 2 phase 3 trials including 198 paediatric patients with moderate-to-severe plaque psoriasis revealed similar tolerability of secukinumab in children and adolescents compared to adult patients [1]. Approximately 1% of all children and adolescents suffer from psoriasis. Although children are less likely to develop the disease than adults, their suffering is particularly severe as the condition negatively impacts their quality of life. In addition, it affects their long-term psychological well-being. The IL-17 blocker secukinumab has been proven to be efficacious in children 6 to <18 years of age in 2 phase 3 trials [2,3]. In these studies, children (aged 6 to <12 years) and adolescents (aged 12 to <18 years) received either 75 mg or 150 mg of secukinumab, depending on their body weight (<50 kg or ≥50 kg). The biologic improved skin symptoms and quali...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on